HomeSearch for 'Treatment'

Treatment - News and Articles about commonly prescribed drugs

Cerevance begins dosing in Part I scientific trial of CVN424 for therapy of Parkinson’s illness

Posted in News on 26th September 2018

Cerevance, a clinical-stage drug discovery and growth firm centered on mind illnesses, at present introduced the beginning of dosing in a Part I first-in-human scientific trial of CVN424, an oral compound being developed for symptomatic therapy of Parkinson’s illness. This primary-in-class compound modulates a novel protein goal selectively expressed in an necessary class of dopamine-responsive neurons within the striatum. The Part I, double-blind, single- and multiple-ascending dose research being performed in america will assess the protection, tolerability, and pharmacokinetic profile of CVN424 in wholesome topics, in addition to results of meals on the compound’s absorption.

“CVN424 prompts key dopamine-responsive motor pathways however not the neurons implicated in levodopa-induced dyskinesias, the uncontrolled actions that afflict so many Parkinson’s sufferers,” famous David Margolin, Senior VP of Scientific and Translational Medication at Cerevance. “This selectivity could permit CVN424 to match the constructive results of the present normal of care, levodopa, with out its negative effects.”

“The completion of preclinical research, the profitable submitting of the IND, and now the initiation of the first-in-human scientific trial for CVN424 are important milestones for our firm,” mentioned Mark Carlton, Ph.D., Chief Scientific Officer of Cerevance. “This compound exemplifies Cerevance’s method of figuring out and modulating therapeutic targets which are selectively expressed in disrupted circuits or susceptible neuronal and glial populations in central nervous system illnesses.”

Supply:

https://www.cerevance.com/copy-of-news-2-21-18-ddf-1

FDA to Overview Eylea for the Therapy of Non-Proliferative Diabetic Retinopathy

Posted in News on 16th September 2018
The FDA has set a target action date for the sBLA of May 13, 2019

The FDA has set a target action date for the sBLA of May 13, 2019

The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) of Eylea (aflibercept; Regeneron) for the treatment for patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema (DME).

Eylea is a vascular endothelial growth factor (VEGF) inhibitor administered as an intravitreal injection. It is currently indicated for the treatment of wet age-related macular degeneration, macular edema following retinal vein occlusion, DME, and diabetic retinopathy in patients with DME. 

The sBLA includes results from the Phase 3 PANORAMA trial, which enrolled 402 patients with NPDR. Results at week 24 showed more than half of patients who received Eylea experienced a 2-step or greater improvement from baseline on the Diabetic Retinopathy Severity Scale vs patients who received a sham injection (58% vs 6%; P<.0001). No new safety signals were observed in the trial. One- year results from the trial are expected later this year.

The FDA has set a Prescription Drug User Fee Act target date of May 13, 2019 for the sBLA.

Scientific trial begins to seek out higher therapy for continual instances of PKDL in Africa

Posted in News on 13th September 2018

A medical trial to discover a higher therapy for extreme or continual instances of put up kala-azar dermal leishmaniasis (PKDL) in Africa has begun in Dooka, Sudan. The target of this medical trial, which is being carried out by the Medicine for Uncared for Ailments initiative (DNDi), a non-profit analysis and improvement group, and the Institute for Endemic Ailments (IEND) on the College of Khartoum, is to shorten the size of hospitalization for PKDL and ship a therapy that’s safer to make use of and simpler to manage.

“As a result of PKDL just isn’t a plague, it has largely been ignored by public well being efforts,” mentioned Dr Fabiana Alves, Head of Visceral Leishmaniasis Programme at DNDi. “However the illness is very stigmatizing for folks affected, and present therapies are merely not ok. That is what we hope to alter with this medical trial.”

PKDL is a type of leishmaniasis, a uncared for parasitical tropical illness, which often develops after an individual has efficiently accomplished visceral leishmaniasis (VL) therapy. The illness is non-lethal however is very stigmatizing due to the lesions that seem on an individual’s face and physique. PKDL is most typical in Jap Africa and South Asia, though there are main variations in epidemiological and medical observations between the 2 areas. In Sudan, 50-60% of VL sufferers will develop PKDL inside six months after the top of the therapy. That is the very best PKDL fee worldwide.

In Africa, the present therapy for PKDL is sodium stibogluconate (SSG), a drug that’s related to excessive threat of toxicity when used for the lengthy therapy period of 40-60 days. SSG can also be impractical, as it’s an injectable drug that must be administered beneath shut supervision in a hospital setting, as a result of its uncomfortable side effects. Because of the limitations of this therapy, solely the extreme or continual instances that don’t self-heal after six months and which can develop disfiguring pores and skin lesions inflicting scars and social stigma are presently handled.

The DNDi-IEND medical trial will assess the protection and efficacy of two therapy mixtures. The primary is a mixture of paromomycin, an injectable therapy, with the oral drug miltefosine, presently not accredited to be used in Africa. The second is a mixture of intravenous liposomal amphotericin B, presently used as a second-line therapy for VL in Africa, with miltefosine.

“If both of those therapy choices are confirmed to be secure and efficacious, PKDL sufferers won’t must spend many days in hospital. They are often handled for a number of days on the hospital, then full the oral therapy at dwelling,” mentioned Dr Brima Younis, IEND, principal investigator for the examine.

The medical trial, which is being carried out beneath the umbrella of the Leishmaniasis East Africa Platform (LEAP), will run for a interval of three years and enroll 110 sufferers from IEND websites. Up to now, 9 sufferers have been enrolled.

“Many scientific questions round PKDL have remained unaddressed,” mentioned Dr Jorge Alvar, Senior Advisor for leishmaniasis at DNDi. “In each Jap Africa and South Asia, PKDL is believed to play an essential position as a reservoir of leishmaniasis parasites that maintains the transmission cycle, and subsequently poses a menace to regulate and elimination efforts of the illness. We’d like extra funding on this uncared for space.”

Supply:

Cassipa Authorised as Upkeep Remedy for Opioid Dependence

Posted in News on 11th September 2018
Cassipa will be supplied in 16mg/4mg strength sublingual films

Cassipa will be supplied in 16mg/4mg strength sublingual films

The Food and Drug Administration (FDA) has approved Cassipa (buprenorphine and naloxone; Teva) sublingual film for the maintenance treatment of opioid dependence. 

Cassipa combines buprenorphine, an opioid (partial agonist-antagonist), and naloxone, an opioid antagonist. It is intended for use with a complete plan that includes counseling and psychosocial support. It should only be used after patient induction and stabilization up to a 16mg dose of buprenorphine using another marketed product. The approval of Cassipa was supported by the FDA’s finding of safety and efficacy for Suboxone sublingual film in addition to pharmacokinetic data specific to Cassipa. 

Oral hypoesthesia, glossodynia, oral mucosal erythema, headache, nausea, vomiting, hyperhidrosis, constipation, signs and symptoms of withdrawal, insomnia, pain, and peripheral edema are the most common adverse events associated with buprenorphine and naloxone sublingual film.

Cassipa will be supplied in 16mg/4mg strength sublingual films and may only be prescribed by Drug Addiction Treatment Act (DATA)-certified prescribers.

FDA Approves Tiglutik for the Remedy of Amyotrophic Lateral Sclerosis

Posted in News on 7th September 2018
Tiglutik is supplied as a thickened riluzole liquid that is intended to ease administration for patients with dysphagia

Tiglutik is supplied as a thickened riluzole liquid that is intended to ease administration for patients with dysphagia

ITF Pharma announced that the Food and Drug Administration (FDA) has approved Tiglutik (riluzole) oral suspension for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The product was previously granted Fast Track Designation and Orphan Drug Designation by the FDA.

Tiglutik is supplied as a thickened riluzole liquid that is intended to ease administration for patients with dysphagia. “The availability of Tiglutik oral suspension precludes the need for manipulation of tablets by patients or caregivers, easing administration and may provide an opportunity for more accurate dosing and enhanced patient compliance,” said Hiroshi Mitsumoto, MD, DSc, Wesley J. Howe professor of neurology at Columbia University at The Neurological Institute of New York and New York-Presbyterian Hospital/Columbia University Medical Center. 

The FDA approval was supported by data from bioavailability studies comparing riluzole tablets and Tiglutik oral suspension. The mechanism by which riluzole exerts its therapeutic effects in ALS patients is unknown, however clinical studies have shown that it modulates glutamate neurotransmission by inhibiting both glutamate release and postsynaptic glutamate receptor signaling.

Tiglutik will be available as a 50mg/10mL strength oral suspension in 300mL bottles in 2-count cartons with supplies. The product is anticipated to launch in mid-October.